BioNTech Announces Acquisition of UK AI Startup InstaDeep
BioNTech has finalized its acquisition of UK-based AI company InstaDeep, aiming to boost its drug discovery and development capabilities. The integration of InstaDeep's machine learning expertise is set to support BioNTech's research in immunotherapies and vaccines.
- Published date: 13-07-2026 10:02 AM
BioNTech SE has announced the completion of its acquisition of InstaDeep, a UK-based artificial intelligence company. The deal, valued at approximately £362 million, aims to strengthen BioNTech's capabilities in AI-driven drug discovery and development.
InstaDeep specializes in advanced machine learning and decision-making systems, which BioNTech plans to integrate into its research pipeline. This move is expected to accelerate the identification of novel immunotherapies and vaccines.
The acquisition reflects BioNTech's ongoing commitment to leveraging digital technologies to enhance its R&D processes. For more details, visit the official press release on BioNTech's website.
BioNTech has finalized its acquisition of UK-based AI company InstaDeep, aiming to boost its drug discovery and development capabilities. The integration of InstaDeep's machine learning expertise is set to support BioNTech's research in immunotherapies and vaccines.